Dergiler / Eskisehir Medical Journal / 2026 / Volume: 7 Issue: 3

Association Between Serum Resistin And Disease Activity In Treated Relapsing–Remitting Multiple Sclerosis

Saltanat Mert(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÖROLOJİ ANABİLİM DALI)0000-0002-9808-7508
Abdulkadir Ermiş(Health Science University, Gaziosmanpaşa Training and Research Hospital, Neurology Department)0000-0001-6933-6950
Hümeyra Öztürk Emre(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR HASTANESİ, BİYOKİMYA DEPARTMANI)0000-0003-0422-4549
Kübra Balcı(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÖROLOJİ ANABİLİM DALI)0009-0005-7910-8763
Edanur Demir(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İSTANBUL BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, NÖROLOJİ ANABİLİM DALI)0009-0004-7678-2210
İbrahim Acır(UNIVERSITY OF HEALTH SCIENCES, İSTANBUL BAKIRKÖY DR. SADİ KONUK TRAINING RESEARCH CENTER)0000-0002-9650-8022
Sayfa
—
Yayın Tarihi
2026-08-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Keywords: multiple sclerosis, resistin, adipokine, neuroinflammation, biomarker, EDSS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: Multiple sclerosis (MS) is an demiyelinating autoimmune disease and characterized with chronic inflammation and neurodegeneration.
📊
Temel Bulgular & Veri:Methods: 41 patients diagnosed with RRMS according to the 2017 McDonald criteria and 40 matched healthy controls were included to the study.
💡
Sonuç & Katkı:Keywords: multiple sclerosis, resistin, adipokine, neuroinflammation, biomarker, EDSS.
🔬Tür:Research Article
📍Kapsam:2017 Verileri
⚙️Değişkenler:multiple sclerosis · resistin · adipokine

Abstract

Introduction: Multiple sclerosis (MS) is an demiyelinating autoimmune disease and characterized with chronic inflammation and neurodegeneration. Resistin is an adipokine secreted from adipose tissue and known to be a pro-inflammatory mediator produced mainly by monocytes and macrophages in humans, has an uncertain role in MS pathogenesis. This study aims to compare serum resistin levels in patients with relapsing-remitting MS (RRMS) with those of healthy controls and to examine the relationship between these levels and key clinical disease parameters. Methods: 41 patients diagnosed with RRMS according to the 2017 McDonald criteria and 40 matched healthy controls were included to the study. Demographic data, clinical characteristics (disease duration, Expanded Disability Status Scale score (EDSS), relapse rates, and blood samples were collected. Serum resistin levels were measured by using the enzyme-linked immunosorbent assay (ELISA) method. The Mann-Whitney U test, Spearman's correlation analysis, independent samples t-test, and Chi-Square test were performed by using the data distribution. Results: Serum resistin levels were similar in MS patients (median: 658.6 pg/mL, range: 118-6000) and in the control group (median: 855.4 pg/mL, range: 182.6-3807.2), with no statistically significant difference (p=0.305). There was no significant correlation between serum resistin levels and the EDSS score (r=-0.056, p=0.728), the number of relapses in the last year (r=-0.006, p=0.968), or the number of relapses in the last two years (r=0.062, p=0.702). Conclusion: The findings suggest that systemic circulating serum resistin levels are not directly associated with the presence of MS and do not serve as a reliable biomarker for clinical activity. The potential role of resistin in MS pathophysiology may be confined to localized inflammatory processes behind the blood-brain barrier rather than systemic circulation. Keywords: multiple sclerosis, resistin, adipokine, neuroinflammation, biomarker, EDSS.

🔖

Bu Makaleye Atıf Yap

Mert, S., Ermiş, A., Emre, H. Ö., Balcı, K., Demir, E., Acır, İ. (2026). Association Between Serum Resistin And Disease Activity In Treated Relapsing–Remitting Multiple Sclerosis. Eskisehir Medical Journal, Volume: 7 Issue: 3. https://ajindex.com/articles/1614174

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (20)

  1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr 21;391(10130):1622-1636. doi:10.1016/S0140-6736(18)30481-1.
  2. Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi:10.1097/MD.0000000000037297.
  3. Ward M, Goldman MD. Epidemiology and pathophysiology of multiple sclerosis. Continuum (Minneap Minn). 2022;28(4):988-1005.
  4. İlgezdi İ, Şener U, Öcek L, Köse Ş, Sarıteke A, Tokuçoğlu F, et al. Copeptin levels in clinically silent multiple sclerosis. Turk J Neurol. 2022;28(4):237-241. doi:10.4274/tnd.2022.95776.
  5. Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:425068. doi:10.1155/2014/425068.
  6. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021 Mar 26;135(6):731-752. doi:10.1042/CS20200895.
  7. Al Hannan F, Culligan KG. Human resistin and the RELM of inflammation in diabesity. Diabetol Metab Syndr. 2015 Jun 18;7:54. doi:10.1186/s13098-015-0050-3.
  8. Emamgholipour S, Eshaghi SM, Hossein-Nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA, et al. Adipocytokine profile, cytokine levels and FOXP3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One. 2013;8(10):e76555. doi:10.1371/journal.pone.0076555.
  9. Correale J, Marrodan M. Multiple sclerosis and obesity: the role of adipokines. Front Immunol. 2022 Nov 15;13:1038393. doi:10.3389/fimmu.2022.1038393.
  10. Michalak S, Jernas L, Tokarz E, Wygladalska-Jernas H, Kozubski W. Serum concentrations of resistin, leptin and adiponectin in multiple sclerosis and myasthenic patients are independent from insulin resistance. Neurology. 2012 Apr;78(1 Suppl):P02.079. doi:10.1212/WNL.78.1_MeetingAbstracts.P02.079.
  11. Loonstra FC, Falize KF, de Ruiter LRJ, Schoonheim MM, Strijbis EMM, Killestein J, et al. Adipokines in multiple sclerosis patients are related to clinical and radiological measures. J Neurol. 2023 Apr;270(4):2018-2030. doi:10.1007/s00415-022-11519-8.
  12. Berghoff M, Hochberg A, Schmid A, Schlegel J, Karrasch T, Kaps M, et al. Quantification and regulation of the adipokines resistin and progranulin in human cerebrospinal fluid. Eur J Clin Invest. 2016;46(1):15-26. doi:10.1111/eci.12558.
  13. Fong CC, Spencer J, Howlett-Prieto Q, Feng X, Reder AT. Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles. Front Neurol. 2023;14:1158487. doi:10.3389/fneur.2023.1158487.
  14. Galota F, Marcheselli S, De Biasi S, Gibellini L, Vitetta F, Fiore A, et al. Impact of high-efficacy therapies for multiple sclerosis on B cells. Cells. 2025;14(8):606. doi:10.3390/cells14080606.
  15. Baharnoori M, Wilson R, Saxena S, Gonzalez CT, Sotiropoulos MG, Keyhanian K, et al. Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients. Mult Scler Relat Disord. 2021 Nov;56:103311. doi:10.1016/j.msard.2021.103311.
  16. Mert S, Acır İ, Öztürk Emre H, Balcı K, Demir E. Serum visfatin in multiple sclerosis: distinct profiles in healthy controls, naive patients, and treated RRMS. Front Immunol. 2026;16:1641260. doi:10.3389/fimmu.2025.1641260.
  17. Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018;7(1):59-85. doi:10.1007/s40120-017-0086-4.
  18. Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James SG, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab. 2007;92(3):1129-1136. doi:10.1210/jc.2006-1841.
  19. Salameh TS, Mortell W, Banks WA. Resistin is associated with blood-brain barrier disruption in mice resistant to diet-induced obesity and treated with topiramate. Diabetes. 2018 Jul;67(Suppl 1):2043-P. doi:10.2337/db18-2043-P.
  20. Adamczyk B, Morawiec N, Kwinta R, Rakoca M, Wawrzyniak S, Zalejska-Fiolka J, et al. Evaluation of selected serum adipocytokines in patients with relapsing-remitting multiple sclerosis treated with immunomodulatory second-line drugs. Int J Mol Sci. 2025 Aug 21;26(16):8070. doi:10.3390/ijms26168070.